IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic Stem Cell Transplantation

Trial Profile

IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic Stem Cell Transplantation

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Oct 2017

At a glance

  • Drugs ALT 803 (Primary)
  • Indications Haematological malignancies
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 23 Oct 2017 Planned End Date changed from 1 Jun 2018 to 1 Jun 2019.
    • 23 Oct 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
    • 23 Oct 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top